SR9009 (Stenabolic)

A new drug known as SR9009, which is presently under development at TSRI (The Scripps Research Institute) has been shown to considerably boost exercise endurance in animal models. Scientists think these discoveries may lead to improved cures for individuals suffering from illnesses that severely limit exercise endurance such as obesity, COPD (chronic obstructive pulmonary disease), congestive heart failure and also in the deterioration of muscle capacity linked with aging.

SR9009: A Drug That Might Cause A Major Breakthrough in Fitness

The drug was developed by Professor Thomas Burris who found that it was capable of reducing obesity in animal models, particularly mice. SR9009 which is an easy to dose oral compound can increase the level of metabolic activity in skeletal muscle of mice. The treated mice became lean, developed larger muscles and had a 50% increase in running abilities which imitates the effects of aerobic exercise.

The SR9009 binds to Rev-erbα (one of the body’s natural molecules) which influences lipid and glucose metabolism in the liver, the creation of fat-storing cells and the reaction of macrophages (cells that eliminate dying or dead cells) during inflammation.

According to Burris;

“The animals actually get muscles like an athlete who has been training. The pattern of gene expression after treatment with SR9009 is that of an oxidative-type muscle— again, just like an athlete.”

SR9009 affects the primary biological clock, which coordinates the rhythm of the body’s activity with the 24-hour phase of day and night.

Recent research show that activation of Rev-erbα with SR9009 resulted to enhanced metabolic activity in skeletal muscle tissue in both culture and in mice. The authors of this new research propose that Rev-erbα affects muscle cells by stimulating both the formation of new mitochondria (more known as the “power plants” of the cell) and the authorization of those mitochondria that are flawed.

If the effects of SR9009 on mice can securely be duplicated for people, the new drug may provide new treatments for obesity and its companions, metabolic syndrome and diabetes. Another area in which SR9009 or a similar drug may present significant benefit is to balance the loss of overall muscle conditioning which transpires as a side effect of reduced activity due to sickness or old age.

Hoping that small-scale medical trials on people start ASAP!

Let us know what you think as well as your hopes for the new drug SR9009 in the comments below.

Source: Scripps Research Institute

The Highest Quality SR9009 SARM

Want to try SR 9009 on your lab rat and see the results for yourself.? You’re in luck, because SARMS1 has recently made their SR9009 SARM trademarked Stenabolic finally available.

Here’s what it looks like…

SR 9009 Stenabolic

 

You click also check out the Stenabolic product page at this link.

         

13 thoughts on “SR9009 (Stenabolic)

  1. JB says:

    Stack: LGD4033 15mg / 100mg laxogenin/25mg Osterine/25mg MK677- daily for 8 weeks. Add Vitamin B6 and B12 High dosage to energize ARs- BAM! Feed the hunger sensibly well, and sleep at least 8 hours daily. Your inner Gorilla will appear!

    • Xenios Hadj says:

      1.Why laxogenin isn’t lgd anabolic enough ?
      2. What about stacking 10 mg lgd with rad 140 8mg ,epicatechin and 4ad as test base? 42days
      Laxogenin as a part of pct or bridge to next cycle after pct .

  2. Phil Slater says:

    I used to take 4 capsules a day in my first two months but I reduced it to 2 capsules after achieving my muscle mass goal. Laxogenin is a big help in for bodybuilders but we should know the facts about it.Thank you for sharing this very informative article.

  3. Glen says:

    Hi I’m using stenabolic for only 2days and I’m eating like a mad man. I’m ravenous. Anybody know why and should this be happening. If I go more than an hour without eating I start to feel weak and weary which goes against what it’s meant to do for you as it states to up your energy levels.

Leave a Reply

Your email address will not be published. Required fields are marked *